CHRS News and Press, Coherus BioSciences Inc.

2024-06-27 14:07:44 ET More on Coherus BioSciences Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway Coherus BioSciences, Inc. (CHRS) Q1 2024 Earnings Call Transcript Coherus BioSciences Non-GAAP EPS of -$0.32 misses by $0.11, revenue of $7...

REDWOOD CITY, Calif., June 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc . (Coherus, Nasdaq: CHRS) today announced it agreed to divest YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend Industrial Co. Ltd. (HKF) for up-front all-cash consideration of $40 million. The closing of the tr...

2024-06-23 11:13:33 ET Summary Since the publication of my last article, Pfizer has continued to surprise me pleasantly. In early May, Pfizer published financial results for the first quarter of 2024, which were enthusiastically received by Wall Street. On June 14, 2024, the c...

2024-06-06 12:38:52 ET Summary FibroGen, Inc. top-line data from the phase 2/3 PanCAN Precision Promise study, using pamrevlumab for the treatment of patients with metastatic pancreatic cancer, expected mid-2024. Topline data from the phase 3 LAPIS study, using pamrevlumab for the...

REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS) today announced that Rita Karachun, CPA, CGMA, most recently Senior Vice President (SVP) and Global Controller for Merck & Co., Inc., (Merck) was appointed to its Board of ...

2024-05-31 12:04:07 ET Summary Coherus BioSciences, Inc. is relying on revenues from existing drugs and its developmental pipeline after selling off a major source of revenue in Cimerli. CHS-114, an anti-CCR8 antibody being developed by CHRS, is set to produce data at the ASCO 202...

REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the 2024 Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 8:30 a.m. Eastern Daylight Time / 5:30 a.m. Pacific Dayl...

CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective depletion of peripheral CCR8+ regulatory T cells (Tregs) was observed and depletion was maintained over the dosing interval, establishing p...

REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the upcoming TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA on Wednesday, May 29, 2024 at 12:00 ...

2024-05-10 00:07:07 ET Coherus BioSciences, Inc. (CHRS) Q1 2024 Earnings Conference Call May 09, 2024 05:00 PM ET Company Participants Jamie Taylor - Head of Investor Relations Denny Lanfear - Chief Executive Officer Paul Reider - Chief Commercial Officer Ros...